Yearly changes in antibacterial activities of cefozopran against various clinical isolates between 1996 and 2000: I. Gram-positive bacteria

Yumiko Suzuki, Chisato Nishinari, Harumi Endo, Chieko Tamura, Keiko Jinbo, Nobuyoshi Hiramatsu, Kazumitsu Akiyama, Tsuneo Koyama

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The in vitro antibacterial activities of cefozopran (CZOP), an agent of cephems, against various clinical isolates obtained between 1996 and 2000 were yearly evaluated and compared with those of other cephems, oxacephems, carbapenems, and penicillins. Fifteen species, 1,062 strains, of Gram-positive bacteria were isolated from the clinical materials annually collected from January to December, and consisted of methicillin-susceptible Staphylococcus aureus (MSSA; n=127), methicillin-resistant Staphylococcus aureus (MRSA; n=123), Staphylococcus epidermidis (n=104), Staphylococcus haemolyticus (n= 58), Streptococcus pyogenes (n=100), Streptococcus agalactiae (n=50), Streptococcus pneumoniae (n=125), Enterococcus faecalis (n=150), Enterococcus faecium (n=50), Enterococcus avium (n=50), and Peptostreptococcus spp. (P anaerobius, P. asaccharolyticus, P. magnus, P. micros, P. prevotii; n=125). CZOP possessed stable antibacterial activities against all strains tested throughout 5 years. The MIC90 of CZOP against MRSA and S. haemolyticus tended to decrease while against S. pneumoniae and Peptostreptococcus spp., tended to increase year by year. However, the MIC90 just changed a little and were consistent with the results from the studies performed until the new drug application approval. Increases in the MIC90 against S. pneumoniae were also observed with cefpirome (CPR), cefepime (CFPM), flomoxef (FMOX), sulbactam/cefoperazone (SBT/CPZ), and imipenem (IPM). Increases in the MIC90 against Peptostreptococcus spp. were also observed with ceftazidime (CAZ), CPR, CFPM, FMOX, SBT/CPZ, and IPM. The decreases in the sensitivities were not always considered to depend upon generation of resistant bacteria because the annual MIC range of each antibacterial agent was almost generally wide every year and the annual sensitivity of each strain to the agents extremely varied. In conclusion, the annual antibacterial activities of CZOP against the Gram-positive bacteria did not considerably change. It, therefore, was suggested that CZOP had maintained high antibacterial activity during 5 years of post-marketing.

Original languageEnglish
Pages (from-to)139-153
Number of pages15
JournalJapanese Journal of Antibiotics
Volume55
Issue number2
Publication statusPublished - 2002
Externally publishedYes

Fingerprint

Gram-Positive Bacteria
cefpirome
Peptostreptococcus
Staphylococcus haemolyticus
Methicillin-Resistant Staphylococcus aureus
Streptococcus pneumoniae
Cefoperazone
Sulbactam
Imipenem
Drug Approval
Enterococcus faecium
Carbapenems
Methicillin
Streptococcus agalactiae
Ceftazidime
Staphylococcus epidermidis
Enterococcus faecalis
Streptococcus pyogenes
Enterococcus
Marketing

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

Suzuki, Y., Nishinari, C., Endo, H., Tamura, C., Jinbo, K., Hiramatsu, N., ... Koyama, T. (2002). Yearly changes in antibacterial activities of cefozopran against various clinical isolates between 1996 and 2000: I. Gram-positive bacteria. Japanese Journal of Antibiotics, 55(2), 139-153.

Yearly changes in antibacterial activities of cefozopran against various clinical isolates between 1996 and 2000 : I. Gram-positive bacteria. / Suzuki, Yumiko; Nishinari, Chisato; Endo, Harumi; Tamura, Chieko; Jinbo, Keiko; Hiramatsu, Nobuyoshi; Akiyama, Kazumitsu; Koyama, Tsuneo.

In: Japanese Journal of Antibiotics, Vol. 55, No. 2, 2002, p. 139-153.

Research output: Contribution to journalArticle

Suzuki, Y, Nishinari, C, Endo, H, Tamura, C, Jinbo, K, Hiramatsu, N, Akiyama, K & Koyama, T 2002, 'Yearly changes in antibacterial activities of cefozopran against various clinical isolates between 1996 and 2000: I. Gram-positive bacteria', Japanese Journal of Antibiotics, vol. 55, no. 2, pp. 139-153.
Suzuki, Yumiko ; Nishinari, Chisato ; Endo, Harumi ; Tamura, Chieko ; Jinbo, Keiko ; Hiramatsu, Nobuyoshi ; Akiyama, Kazumitsu ; Koyama, Tsuneo. / Yearly changes in antibacterial activities of cefozopran against various clinical isolates between 1996 and 2000 : I. Gram-positive bacteria. In: Japanese Journal of Antibiotics. 2002 ; Vol. 55, No. 2. pp. 139-153.
@article{8953549d319e4c05a2997abb6e46304b,
title = "Yearly changes in antibacterial activities of cefozopran against various clinical isolates between 1996 and 2000: I. Gram-positive bacteria",
abstract = "The in vitro antibacterial activities of cefozopran (CZOP), an agent of cephems, against various clinical isolates obtained between 1996 and 2000 were yearly evaluated and compared with those of other cephems, oxacephems, carbapenems, and penicillins. Fifteen species, 1,062 strains, of Gram-positive bacteria were isolated from the clinical materials annually collected from January to December, and consisted of methicillin-susceptible Staphylococcus aureus (MSSA; n=127), methicillin-resistant Staphylococcus aureus (MRSA; n=123), Staphylococcus epidermidis (n=104), Staphylococcus haemolyticus (n= 58), Streptococcus pyogenes (n=100), Streptococcus agalactiae (n=50), Streptococcus pneumoniae (n=125), Enterococcus faecalis (n=150), Enterococcus faecium (n=50), Enterococcus avium (n=50), and Peptostreptococcus spp. (P anaerobius, P. asaccharolyticus, P. magnus, P. micros, P. prevotii; n=125). CZOP possessed stable antibacterial activities against all strains tested throughout 5 years. The MIC90 of CZOP against MRSA and S. haemolyticus tended to decrease while against S. pneumoniae and Peptostreptococcus spp., tended to increase year by year. However, the MIC90 just changed a little and were consistent with the results from the studies performed until the new drug application approval. Increases in the MIC90 against S. pneumoniae were also observed with cefpirome (CPR), cefepime (CFPM), flomoxef (FMOX), sulbactam/cefoperazone (SBT/CPZ), and imipenem (IPM). Increases in the MIC90 against Peptostreptococcus spp. were also observed with ceftazidime (CAZ), CPR, CFPM, FMOX, SBT/CPZ, and IPM. The decreases in the sensitivities were not always considered to depend upon generation of resistant bacteria because the annual MIC range of each antibacterial agent was almost generally wide every year and the annual sensitivity of each strain to the agents extremely varied. In conclusion, the annual antibacterial activities of CZOP against the Gram-positive bacteria did not considerably change. It, therefore, was suggested that CZOP had maintained high antibacterial activity during 5 years of post-marketing.",
author = "Yumiko Suzuki and Chisato Nishinari and Harumi Endo and Chieko Tamura and Keiko Jinbo and Nobuyoshi Hiramatsu and Kazumitsu Akiyama and Tsuneo Koyama",
year = "2002",
language = "English",
volume = "55",
pages = "139--153",
journal = "The Journal of antibiotics. Ser. B",
issn = "0368-2781",
publisher = "Japan Antibiotics Research Association",
number = "2",

}

TY - JOUR

T1 - Yearly changes in antibacterial activities of cefozopran against various clinical isolates between 1996 and 2000

T2 - I. Gram-positive bacteria

AU - Suzuki, Yumiko

AU - Nishinari, Chisato

AU - Endo, Harumi

AU - Tamura, Chieko

AU - Jinbo, Keiko

AU - Hiramatsu, Nobuyoshi

AU - Akiyama, Kazumitsu

AU - Koyama, Tsuneo

PY - 2002

Y1 - 2002

N2 - The in vitro antibacterial activities of cefozopran (CZOP), an agent of cephems, against various clinical isolates obtained between 1996 and 2000 were yearly evaluated and compared with those of other cephems, oxacephems, carbapenems, and penicillins. Fifteen species, 1,062 strains, of Gram-positive bacteria were isolated from the clinical materials annually collected from January to December, and consisted of methicillin-susceptible Staphylococcus aureus (MSSA; n=127), methicillin-resistant Staphylococcus aureus (MRSA; n=123), Staphylococcus epidermidis (n=104), Staphylococcus haemolyticus (n= 58), Streptococcus pyogenes (n=100), Streptococcus agalactiae (n=50), Streptococcus pneumoniae (n=125), Enterococcus faecalis (n=150), Enterococcus faecium (n=50), Enterococcus avium (n=50), and Peptostreptococcus spp. (P anaerobius, P. asaccharolyticus, P. magnus, P. micros, P. prevotii; n=125). CZOP possessed stable antibacterial activities against all strains tested throughout 5 years. The MIC90 of CZOP against MRSA and S. haemolyticus tended to decrease while against S. pneumoniae and Peptostreptococcus spp., tended to increase year by year. However, the MIC90 just changed a little and were consistent with the results from the studies performed until the new drug application approval. Increases in the MIC90 against S. pneumoniae were also observed with cefpirome (CPR), cefepime (CFPM), flomoxef (FMOX), sulbactam/cefoperazone (SBT/CPZ), and imipenem (IPM). Increases in the MIC90 against Peptostreptococcus spp. were also observed with ceftazidime (CAZ), CPR, CFPM, FMOX, SBT/CPZ, and IPM. The decreases in the sensitivities were not always considered to depend upon generation of resistant bacteria because the annual MIC range of each antibacterial agent was almost generally wide every year and the annual sensitivity of each strain to the agents extremely varied. In conclusion, the annual antibacterial activities of CZOP against the Gram-positive bacteria did not considerably change. It, therefore, was suggested that CZOP had maintained high antibacterial activity during 5 years of post-marketing.

AB - The in vitro antibacterial activities of cefozopran (CZOP), an agent of cephems, against various clinical isolates obtained between 1996 and 2000 were yearly evaluated and compared with those of other cephems, oxacephems, carbapenems, and penicillins. Fifteen species, 1,062 strains, of Gram-positive bacteria were isolated from the clinical materials annually collected from January to December, and consisted of methicillin-susceptible Staphylococcus aureus (MSSA; n=127), methicillin-resistant Staphylococcus aureus (MRSA; n=123), Staphylococcus epidermidis (n=104), Staphylococcus haemolyticus (n= 58), Streptococcus pyogenes (n=100), Streptococcus agalactiae (n=50), Streptococcus pneumoniae (n=125), Enterococcus faecalis (n=150), Enterococcus faecium (n=50), Enterococcus avium (n=50), and Peptostreptococcus spp. (P anaerobius, P. asaccharolyticus, P. magnus, P. micros, P. prevotii; n=125). CZOP possessed stable antibacterial activities against all strains tested throughout 5 years. The MIC90 of CZOP against MRSA and S. haemolyticus tended to decrease while against S. pneumoniae and Peptostreptococcus spp., tended to increase year by year. However, the MIC90 just changed a little and were consistent with the results from the studies performed until the new drug application approval. Increases in the MIC90 against S. pneumoniae were also observed with cefpirome (CPR), cefepime (CFPM), flomoxef (FMOX), sulbactam/cefoperazone (SBT/CPZ), and imipenem (IPM). Increases in the MIC90 against Peptostreptococcus spp. were also observed with ceftazidime (CAZ), CPR, CFPM, FMOX, SBT/CPZ, and IPM. The decreases in the sensitivities were not always considered to depend upon generation of resistant bacteria because the annual MIC range of each antibacterial agent was almost generally wide every year and the annual sensitivity of each strain to the agents extremely varied. In conclusion, the annual antibacterial activities of CZOP against the Gram-positive bacteria did not considerably change. It, therefore, was suggested that CZOP had maintained high antibacterial activity during 5 years of post-marketing.

UR - http://www.scopus.com/inward/record.url?scp=0036246283&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036246283&partnerID=8YFLogxK

M3 - Article

C2 - 12071093

AN - SCOPUS:0036246283

VL - 55

SP - 139

EP - 153

JO - The Journal of antibiotics. Ser. B

JF - The Journal of antibiotics. Ser. B

SN - 0368-2781

IS - 2

ER -